Skip to main content

Peer Review reports

From: Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study

Original Submission
9 Sep 2022 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
22 Oct 2022 Reviewed Reviewer Report
26 Oct 2022 Reviewed Reviewer Report - Takaaki Mizuno
1 Dec 2022 Author responded Author comments - Yuankai Shi
Resubmission - Version 4
1 Dec 2022 Submitted Manuscript version 4
12 Dec 2022 Author responded Author comments - Yuankai Shi
Resubmission - Version 5
12 Dec 2022 Submitted Manuscript version 5
20 Dec 2022 Author responded Author comments - Yuankai Shi
Resubmission - Version 6
20 Dec 2022 Submitted Manuscript version 6
29 Dec 2022 Author responded Author comments - Yuankai Shi
Resubmission - Version 7
29 Dec 2022 Submitted Manuscript version 7
Publishing
30 Dec 2022 Editorially accepted
11 Apr 2023 Article published 10.1186/s12885-022-10500-y

You can find further information about peer review here.

Back to article page